Evolus Eyes 2027 Sculpt Launch as Filler Portfolio Expands and Revenue Grows
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. 2026 Q3 - Results - Earnings Call Presentation
Evolus (EOLS) Q3 2026 Earnings Call Transcript
Evolus Inc (EOLS) (Q3 2026) Earnings Call Highlights: Fourth Consecutive Positive Adjusted ...
BTIG Maintains Buy on Evolus, Raises Price Target to $15
What Evolus (EOLS) Said on Its Q3 Earnings Call
Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates
Evolus, Inc. (EOLS) Q3 2026 Earnings Call Transcript
Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook
Evolus Q3 2026 Earnings Call Transcript
Evolus Affirms FY2026 Sales Guidance of $330.000M-$337.000M vs $334.100M Est
Evolus Q3 EPS $(0.19) Misses $(0.17) Estimate, Sales $78.000M Beat $77.662M Estimate
Evolus to Participate in Upcoming Investor Conferences in New York and London
Evolus to Report Third Quarter Financial Results on November 4, 2026
Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
FDA Flags Evolus’ Jeuveau Instagram Promotion As Misleading, Seeks Corrective Action
Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug
FDA Release Letter Date Sept. 28: Sends Letter To Evolus, Terms Co.'s Claims About JEUVEAU As Misleading
Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.